Abstract Library

#4111 Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Introduction: Peptide receptor radionuclide therapy (PRRT) presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known.

Conference:

Presenting Author: Warfvinge C

Authors: Warfvinge C, Gustafsson J, Roth D, Tennvall J, Svensson J,

Keywords: PRRT, Neuroendocrine tumor, dose-response, dosimetry,

#3875 Investigation on dose-toxicity and dose-response relationship in neuroendocrine liver metastases treated with Holmium-166 radioembolization

Introduction: Radioembolization is a viable treatment option for neuroendocrine liver metastases.

Conference:

Presenting Author: Ramdhani K

Authors: Ramdhani K, Verduin J, Smits M, Bruijnen R, Lam M,

Keywords: Radioembolization, SIRT, holmium-166, neuroendocrine liver metastasis,

#3800 Correlation between early response and lesion dosimetry in patients with advanced neuroendocrine tumor (NET) treated with radioligand therapy (RLT)

Introduction: The identification of predictive parameters of response to radioligand therapy (RLT) in NET patients is essential in order to avoid futile therapy toxicities. The relation between the tumor absorbed dose and therapy response has so far not been established.

Conference:

Presenting Author: Durmo R

Authors: Durmo R, Fioroni F, Grassi E, Coruzzi C, Giulia B,

Keywords: RLT, Dosimetry,

#3563 Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?

Introduction: Tumor dosimetry protocols following Peptide Receptor Radionuclide Therapy (PRRT) have not yet been standardised and tumor absorbed dose does not hold clear value in predicting response to treatment.

Conference:

Presenting Author: Mileva M

Authors: Mileva M, Marin G, Levillain H, van Bogaert C, Critchi G,

Keywords: PRRT, tumor dose, 68Ga-DOTATATE, SUVmax, response,

#3396 Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuro-endocrine tumor liver metastases

Introduction: In radioembolization, response is achieved through the irradiation and damaging of tumor DNA, while treatment toxicity is mainly related to healthy liver dose. Therefore, optimizing the dose in tumors while minimizing the healthy liver dose is deemed important. However, for hepatic metastases of neuroendocrine tumors, a dose-response relationship has not been established yet.

Conference:

Presenting Author: Ebbers S

Authors: Ebbers S, van Roekel C, Braat M, Barentsz M, Lam M,

Keywords: dose-response, neuroendocrine neoplasm, SIRT, 90y, radioembolization, liver metastasis,